Company intelligence / Profile preview

Kula Bio

Boston, Massachusetts, United Stateskulabio.com ↗

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Kula Bio has developed and commercialized "Kula-N," a next-generation sustainable nitrogen biofertilizer based on proprietary enhancements to the microbe Xanthobacter autotrophicus. The product has been validated across geographies and crop types as an effective replacement for traditional synthetic fertilizers. It improves yield while reducing greenhouse gas emissions and nutrient runoff associated with conventional fertilizers. No clinical results as it does not operate in human/animal therapeutics.

Therapeutic areas: Other
Modalities: Microbial therapyLive biotherapeutic product therapy (for plants/agriculture)
Industry: Agriculture & AgTech

Partnerships

Member of American Alliance for Biomanufacturing (AAB) as of May 2025

Beyond the preview

Go deeper on Kula Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kula Bio.

Explore the full profile